Global Cell-based Flu Vaccine Market Growth 2022-2028
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Cell-based Flu Vaccine Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Cell-based Flu Vaccine by Geographic Region, 2017, 2022 & 2028
- 2.1.3 World Current & Future Analysis for Cell-based Flu Vaccine by Country/Region, 2017, 2022 & 2028
- 2.2 Cell-based Flu Vaccine Segment by Type
- 2.2.1 Trivalent Influenza Vaccine
- 2.2.2 Quadrivalent Influenza Vaccine
- 2.3 Cell-based Flu Vaccine Sales by Type
- 2.3.1 Global Cell-based Flu Vaccine Sales Market Share by Type (2017-2022)
- 2.3.2 Global Cell-based Flu Vaccine Revenue and Market Share by Type (2017-2022)
- 2.3.3 Global Cell-based Flu Vaccine Sale Price by Type (2017-2022)
- 2.4 Cell-based Flu Vaccine Segment by Application
- 2.4.1 Aldults
- 2.4.2 Children
- 2.5 Cell-based Flu Vaccine Sales by Application
- 2.5.1 Global Cell-based Flu Vaccine Sale Market Share by Application (2017-2022)
- 2.5.2 Global Cell-based Flu Vaccine Revenue and Market Share by Application (2017-2022)
- 2.5.3 Global Cell-based Flu Vaccine Sale Price by Application (2017-2022)
3 Global Cell-based Flu Vaccine by Company
- 3.1 Global Cell-based Flu Vaccine Breakdown Data by Company
- 3.1.1 Global Cell-based Flu Vaccine Annual Sales by Company (2020-2022)
- 3.1.2 Global Cell-based Flu Vaccine Sales Market Share by Company (2020-2022)
- 3.2 Global Cell-based Flu Vaccine Annual Revenue by Company (2020-2022)
- 3.2.1 Global Cell-based Flu Vaccine Revenue by Company (2020-2022)
- 3.2.2 Global Cell-based Flu Vaccine Revenue Market Share by Company (2020-2022)
- 3.3 Global Cell-based Flu Vaccine Sale Price by Company
- 3.4 Key Manufacturers Cell-based Flu Vaccine Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Cell-based Flu Vaccine Product Location Distribution
- 3.4.2 Players Cell-based Flu Vaccine Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Cell-based Flu Vaccine by Geographic Region
- 4.1 World Historic Cell-based Flu Vaccine Market Size by Geographic Region (2017-2022)
- 4.1.1 Global Cell-based Flu Vaccine Annual Sales by Geographic Region (2017-2022)
- 4.1.2 Global Cell-based Flu Vaccine Annual Revenue by Geographic Region
- 4.2 World Historic Cell-based Flu Vaccine Market Size by Country/Region (2017-2022)
- 4.2.1 Global Cell-based Flu Vaccine Annual Sales by Country/Region (2017-2022)
- 4.2.2 Global Cell-based Flu Vaccine Annual Revenue by Country/Region
- 4.3 Americas Cell-based Flu Vaccine Sales Growth
- 4.4 APAC Cell-based Flu Vaccine Sales Growth
- 4.5 Europe Cell-based Flu Vaccine Sales Growth
- 4.6 Middle East & Africa Cell-based Flu Vaccine Sales Growth
5 Americas
- 5.1 Americas Cell-based Flu Vaccine Sales by Country
- 5.1.1 Americas Cell-based Flu Vaccine Sales by Country (2017-2022)
- 5.1.2 Americas Cell-based Flu Vaccine Revenue by Country (2017-2022)
- 5.2 Americas Cell-based Flu Vaccine Sales by Type
- 5.3 Americas Cell-based Flu Vaccine Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Cell-based Flu Vaccine Sales by Region
- 6.1.1 APAC Cell-based Flu Vaccine Sales by Region (2017-2022)
- 6.1.2 APAC Cell-based Flu Vaccine Revenue by Region (2017-2022)
- 6.2 APAC Cell-based Flu Vaccine Sales by Type
- 6.3 APAC Cell-based Flu Vaccine Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
7 Europe
- 7.1 Europe Cell-based Flu Vaccine by Country
- 7.1.1 Europe Cell-based Flu Vaccine Sales by Country (2017-2022)
- 7.1.2 Europe Cell-based Flu Vaccine Revenue by Country (2017-2022)
- 7.2 Europe Cell-based Flu Vaccine Sales by Type
- 7.3 Europe Cell-based Flu Vaccine Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Cell-based Flu Vaccine by Country
- 8.1.1 Middle East & Africa Cell-based Flu Vaccine Sales by Country (2017-2022)
- 8.1.2 Middle East & Africa Cell-based Flu Vaccine Revenue by Country (2017-2022)
- 8.2 Middle East & Africa Cell-based Flu Vaccine Sales by Type
- 8.3 Middle East & Africa Cell-based Flu Vaccine Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Cell-based Flu Vaccine
- 10.3 Manufacturing Process Analysis of Cell-based Flu Vaccine
- 10.4 Industry Chain Structure of Cell-based Flu Vaccine
11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Cell-based Flu Vaccine Distributors
- 11.3 Cell-based Flu Vaccine Customer
12 World Forecast Review for Cell-based Flu Vaccine by Geographic Region
- 12.1 Global Cell-based Flu Vaccine Market Size Forecast by Region
- 12.1.1 Global Cell-based Flu Vaccine Forecast by Region (2023-2028)
- 12.1.2 Global Cell-based Flu Vaccine Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Cell-based Flu Vaccine Forecast by Type
- 12.7 Global Cell-based Flu Vaccine Forecast by Application
13 Key Players Analysis
- 13.1 GlaxoSmithKline
- 13.1.1 GlaxoSmithKline Company Information
- 13.1.2 GlaxoSmithKline Cell-based Flu Vaccine Product Offered
- 13.1.3 GlaxoSmithKline Cell-based Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.1.4 GlaxoSmithKline Main Business Overview
- 13.1.5 GlaxoSmithKline Latest Developments
- 13.2 Sanofi
- 13.2.1 Sanofi Company Information
- 13.2.2 Sanofi Cell-based Flu Vaccine Product Offered
- 13.2.3 Sanofi Cell-based Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.2.4 Sanofi Main Business Overview
- 13.2.5 Sanofi Latest Developments
- 13.3 Pfizer
- 13.3.1 Pfizer Company Information
- 13.3.2 Pfizer Cell-based Flu Vaccine Product Offered
- 13.3.3 Pfizer Cell-based Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.3.4 Pfizer Main Business Overview
- 13.3.5 Pfizer Latest Developments
- 13.4 MedImmune, LLC
- 13.4.1 MedImmune, LLC Company Information
- 13.4.2 MedImmune, LLC Cell-based Flu Vaccine Product Offered
- 13.4.3 MedImmune, LLC Cell-based Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.4.4 MedImmune, LLC Main Business Overview
- 13.4.5 MedImmune, LLC Latest Developments
- 13.5 Intravacc
- 13.5.1 Intravacc Company Information
- 13.5.2 Intravacc Cell-based Flu Vaccine Product Offered
- 13.5.3 Intravacc Cell-based Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.5.4 Intravacc Main Business Overview
- 13.5.5 Intravacc Latest Developments
- 13.6 CSL Limited
- 13.6.1 CSL Limited Company Information
- 13.6.2 CSL Limited Cell-based Flu Vaccine Product Offered
- 13.6.3 CSL Limited Cell-based Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.6.4 CSL Limited Main Business Overview
- 13.6.5 CSL Limited Latest Developments
- 13.7 E. Merck KG
- 13.7.1 E. Merck KG Company Information
- 13.7.2 E. Merck KG Cell-based Flu Vaccine Product Offered
- 13.7.3 E. Merck KG Cell-based Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.7.4 E. Merck KG Main Business Overview
- 13.7.5 E. Merck KG Latest Developments
- 13.8 Novartis
- 13.8.1 Novartis Company Information
- 13.8.2 Novartis Cell-based Flu Vaccine Product Offered
- 13.8.3 Novartis Cell-based Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.8.4 Novartis Main Business Overview
- 13.8.5 Novartis Latest Developments
- 13.9 Danaher Corporation
- 13.9.1 Danaher Corporation Company Information
- 13.9.2 Danaher Corporation Cell-based Flu Vaccine Product Offered
- 13.9.3 Danaher Corporation Cell-based Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.9.4 Danaher Corporation Main Business Overview
- 13.9.5 Danaher Corporation Latest Developments
- 13.10 SINOVAC
- 13.10.1 SINOVAC Company Information
- 13.10.2 SINOVAC Cell-based Flu Vaccine Product Offered
- 13.10.3 SINOVAC Cell-based Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.10.4 SINOVAC Main Business Overview
- 13.10.5 SINOVAC Latest Developments
14 Research Findings and Conclusion
As the global economy mends, the 2021 growth of Cell-based Flu Vaccine will have significant change from previous year. According to our (LP Information) latest study, the global Cell-based Flu Vaccine market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Cell-based Flu Vaccine market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Cell-based Flu Vaccine market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Cell-based Flu Vaccine market, reaching US$ million by the year 2028. As for the Europe Cell-based Flu Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Cell-based Flu Vaccine players cover GlaxoSmithKline, Sanofi, Pfizer, and MedImmune, LLC, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Cell-based Flu Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Aldults
Children
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
GlaxoSmithKline
Sanofi
Pfizer
MedImmune, LLC
Intravacc
CSL Limited
E. Merck KG
Novartis
Danaher Corporation
SINOVAC